Galectin Therapeutics Statistics
Total Valuation
GALT has a market cap or net worth of $93.52 million. The enterprise value is $171.04 million.
Important Dates
The next estimated earnings date is Friday, March 28, 2025, before market open.
| Earnings Date | Mar 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
GALT has 62.76 million shares outstanding. The number of shares has increased by 4.27% in one year.
| Current Share Class | 62.76M |
| Shares Outstanding | 62.76M |
| Shares Change (YoY) | +4.27% |
| Shares Change (QoQ) | +0.07% |
| Owned by Insiders (%) | 20.49% |
| Owned by Institutions (%) | 16.16% |
| Float | 43.90M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | -1.01 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.13
| Current Ratio | 1.13 |
| Quick Ratio | 1.07 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8.49 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -96.72% |
| Return on Invested Capital (ROIC) | -207.88% |
| Return on Capital Employed (ROCE) | -1,065.32% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.23M |
| Employee Count | 14 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -19.89% in the last 52 weeks. The beta is 0.82, so GALT's price volatility has been lower than the market average.
| Beta (5Y) | 0.82 |
| 52-Week Price Change | -19.89% |
| 50-Day Moving Average | 1.37 |
| 200-Day Moving Average | 2.30 |
| Relative Strength Index (RSI) | 60.84 |
| Average Volume (20 Days) | 264,837 |
Short Selling Information
The latest short interest is 7.98 million, so 12.71% of the outstanding shares have been sold short.
| Short Interest | 7.98M |
| Short Previous Month | 8.16M |
| Short % of Shares Out | 12.71% |
| Short % of Float | 18.17% |
| Short Ratio (days to cover) | 20.72 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -39.57M |
| Pretax Income | -44.65M |
| Net Income | -45.23M |
| EBITDA | n/a |
| EBIT | -39.57M |
| Earnings Per Share (EPS) | -$0.73 |
Full Income StatementBalance Sheet
The company has $27.06 million in cash and $104.59 million in debt, giving a net cash position of -$77.53 million or -$1.24 per share.
| Cash & Cash Equivalents | 27.06M |
| Total Debt | 104.59M |
| Net Cash | -77.53M |
| Net Cash Per Share | -$1.24 |
| Equity (Book Value) | -92.48M |
| Book Value Per Share | -1.52 |
| Working Capital | 3.41M |
Full Balance SheetCash Flow
| Operating Cash Flow | -33.68M |
| Capital Expenditures | n/a |
| Free Cash Flow | -33.68M |
| FCF Per Share | -$0.54 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |